Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complete pathologic response to neoadjuvant icotinib in stage IIIA EGFR-mutant lung adenosquamous carcinoma: A case report.

Medicine - 26 Jan 2024

Cai Zhongfu, Huang Jishui, Dai Wenliang, Li Xiaobin, Hong Wencong, Hong Youzhi

Abstract excerpt

RATIONALE: Radical surgery offers the best chance of cure, it is critical to expand surgery opportunities for patients with early-stage lung cancer to prolong overall survival. However, evidence is still limited regarding the application of neoadjuvant therapy with EGFR-tyrosine kinase. PATIENT: The patient reported here was a 53-year-old woman with right lower lung adenosquamous carcinoma. DIAGNOSES: The lung...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Adenosquamous
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Crown Ethers

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Neoadjuvant Therapy

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 38277579
DOI: 10.1097/MD.0000000000036214
PMCID: PMC10817100

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complete pathologic response to neoadjuvant icotinib in stage IIIA EGFR-mutant lung adenosquamous carcinoma: A case report.PMID 38277579Read ↗

[Erlotinib plus Bevacizumab Therapy for Postoperative Recurrence of Adenosquamous Cell Carcinoma Harboring EGFR Mutation-A Case Report].Semantic proximity Read ↗

Clinicopathological characteristics and prognosis of patients with adenosquamous lung carcinoma.Semantic proximity Read ↗

[Clinicopathologic Features and Prognostic Implications in 72 Cases with Lung Adenosquamous Carcinoma].Semantic proximity Read ↗

Clinicopathological Features and Survival Outcomes of Resected Lung Adenosquamous Carcinoma: Results From a Nationwide Japanese Registry Data.Semantic proximity Read ↗

Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report.Semantic proximity Read ↗

Adenoid Cystic Carcinoma of the Lung with an EGFR Mutation.Semantic proximity Read ↗

Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.Semantic proximity Read ↗

Clinical Outcomes of Different Generations of EGFR Tyrosine Kinase Inhibitors in Advanced Lung Adenosquamous Carcinoma.Semantic proximity Read ↗

Predictive and prognostic value of preoperative serum tumor markers in resectable adenosqamous lung carcinoma.Semantic proximity Read ↗

Biomarker expression and druggable gene alterations for development of an appropriate therapeutic protocol for pulmonary adenosquamous carcinoma.Semantic proximity Read ↗

Significant Benefits of Osimertinib Against Adenosquamous Carcinoma Harboring Germline T790M Mutation.Semantic proximity Read ↗

Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.